Literature DB >> 20526219

Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.

Kari Nielsen1, Katja Harbst, Anna Måsbäck, Göran Jönsson, Ake Borg, Håkan Olsson, Christian Ingvar.   

Abstract

Phenotypic characteristics were examined in melanoma-prone southern Swedish CDKN2A (p16-113insArg/p14ARF-128insSer) mutation families, in relation to the CDKN2A genotype, nevi, clinically atypical nevi (CAN) and melanoma. Individuals from eight melanoma-prone families, with index patients carrying the CDKN2A mutation, were offered skin examinations and genotyping (CDKN2A and MC1R). Ninety-three individuals above 18 years of age participated; 29 invasive melanomas in 16 patients were recorded, all in the 38 verified CDKN2A mutation carriers. Median age at diagnosis was 36 years. Several MC1R variants were observed. A significant correlation to CAN (P=0.01) and red hair colour (P=0.02) could be confirmed in melanoma patients. A positive mutation status (CDKN2A) was correlated to one or more CAN (P=0.007) but neither to blue eyes, red hair colour, heavy freckling nor high number of nevi. For mutation carriers, median total naevus count was 24 and interquartile range was 12-47 (mean 31); whereas for the whole cohort, median total naevus count was 12 and interquartile range was 5-25 (mean 22). No participant fulfilled the atypical mole syndrome phenotype criteria. Melanomas were diagnosed only in mutation carriers, and melanoma diagnosis was statistically correlated to the presence of one or more CAN and red hair colour, supporting the possible synergistic effect of a MC1R mutation on increased risk of melanoma in patients with a CDKN2A mutation. Family history, with verified tumour diagnoses, remains an important clinical tool for finding mutation carriers for referral to clinical geneticists and simultaneous presence of CAN in probable mutation carriers might strengthen this indication. The atypical mole syndrome phenotype was, however, not verified in the studied families and total naevus counts were low.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20526219     DOI: 10.1097/CMR.0b013e3283341339

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  4 in total

1.  Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.

Authors:  Nicholas J Taylor; Nandita Mitra; Alisa M Goldstein; Margaret A Tucker; Marie-Françoise Avril; Esther Azizi; Wilma Bergman; D Timothy Bishop; Brigitte Bressac-de Paillerets; William Bruno; Donato Calista; Lisa A Cannon-Albright; Francisco Cuellar; Anne E Cust; Florence Demenais; David E Elder; Anne-Marie Gerdes; Paola Ghiorzo; Thais C Grazziotin; Johan Hansson; Mark Harland; Nicholas K Hayward; Marko Hocevar; Veronica Höiom; Christian Ingvar; Maria Teresa Landi; Gilles Landman; Alejandra Larre-Borges; Sancy A Leachman; Graham J Mann; Eduardo Nagore; Håkan Olsson; Jane M Palmer; Barbara Perić; Dace Pjanova; Antonia Pritchard; Susana Puig; Nienke van der Stoep; Karin A W Wadt; Linda Whitaker; Xiaohong R Yang; Julia A Newton Bishop; Nelleke A Gruis; Peter A Kanetsky
Journal:  J Invest Dermatol       Date:  2017-08-19       Impact factor: 8.551

Review 2.  Dysplastic nevi and melanoma.

Authors:  Alisa M Goldstein; Margaret A Tucker
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

3.  Interaction of CDKN2A and sun exposure in the etiology of melanoma in the general population.

Authors:  Marianne Berwick; Colin B Begg; Bruce K Armstrong; Anne S Reiner; Nancy E Thomas; Linda S Cook; Irene Orlow; Anne Kricker; Loraine D Marrett; Stephen B Gruber; Hoda Anton-Culver; Robert C Millikan; Richard P Gallagher; Terry Dwyer; Stefano Rosso; Peter A Kanetsky; Julia Lee-Taylor
Journal:  J Invest Dermatol       Date:  2011-08-11       Impact factor: 8.551

4.  The Impact of Longitudinal Surveillance on Tumor Thickness for Melanoma-Prone Families with and without Pathogenic Germline Variants of CDKN2A and CDK4.

Authors:  Alisa M Goldstein; Margaret A Tucker; Michael R Sargen; Ruth M Pfeiffer; David E Elder; Xiaohong R Yang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-04       Impact factor: 4.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.